CARA vs. NRXP, CASI, HCWB, DRRX, EYEN, DARE, FBIO, JAGX, VYNE, and UNCY
Should you be buying Cara Therapeutics stock or one of its competitors? The main competitors of Cara Therapeutics include NRx Pharmaceuticals (NRXP), CASI Pharmaceuticals (CASI), HCW Biologics (HCWB), DURECT (DRRX), Eyenovia (EYEN), Daré Bioscience (DARE), Fortress Biotech (FBIO), Jaguar Health (JAGX), VYNE Therapeutics (VYNE), and Unicycive Therapeutics (UNCY). These companies are all part of the "pharmaceutical preparations" industry.
Cara Therapeutics (NASDAQ:CARA) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, community ranking, profitability and risk.
NRx Pharmaceuticals has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. NRx Pharmaceuticals' return on equity of 0.00% beat Cara Therapeutics' return on equity.
In the previous week, Cara Therapeutics had 1 more articles in the media than NRx Pharmaceuticals. MarketBeat recorded 4 mentions for Cara Therapeutics and 3 mentions for NRx Pharmaceuticals. NRx Pharmaceuticals' average media sentiment score of 1.42 beat Cara Therapeutics' score of 0.74 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.
Cara Therapeutics currently has a consensus price target of $11.12, suggesting a potential upside of 1,503.69%. Given Cara Therapeutics' higher possible upside, equities analysts clearly believe Cara Therapeutics is more favorable than NRx Pharmaceuticals.
Cara Therapeutics received 660 more outperform votes than NRx Pharmaceuticals when rated by MarketBeat users. However, 100.00% of users gave NRx Pharmaceuticals an outperform vote while only 75.03% of users gave Cara Therapeutics an outperform vote.
Cara Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500. Comparatively, NRx Pharmaceuticals has a beta of 1.15, indicating that its share price is 15% more volatile than the S&P 500.
44.7% of Cara Therapeutics shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 3.1% of Cara Therapeutics shares are owned by company insiders. Comparatively, 21.1% of NRx Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
NRx Pharmaceuticals has lower revenue, but higher earnings than Cara Therapeutics. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Cara Therapeutics beats NRx Pharmaceuticals on 9 of the 16 factors compared between the two stocks.
Get Cara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cara Therapeutics Competitors List
Related Companies and Tools
